Aligos Therapeutics, Inc.
Customers
2
0 disclosed, 1 federal agency
Suppliers
0
None disclosed
Largest customer
—
No % disclosed
Named-customer revenue
—
No estimate available
Federal obligations
$1.5M
FY2025 · USAspending.gov
Latest period
Dec 31, 2023
10-K filed 2026-03-05
Customers 1
Companies ALGS discloses as major customers, as a share of ALGS revenue. 0 active, 1 lapsed.
| Company | % of ALGS revenue | Est. revenue | Period | Trend | Status | Source |
|---|---|---|---|---|---|---|
| Amoytop Biotech Co., Ltd Non-SEC Amoytop Biotech Co., Ltd |
Named | — | FY 2023-12-31 | — | Lapsed Last seen 2023-12-31 |
10-K 2026-03-05 |
Revenue from contracts with customers Agreement with AmoytopIn May 2023, the Company and Amoytop Biotech Co., Ltd (Amoytop) entered into a Research Collaboration and Development Agreement (the Amoytop Agreement) with a focus on nucleic acid technology for HBV treatment, with the Company granting to Amoytop an exclusive, time-limited option to enter into an exclusive, territory-limited license to develop and commercialize such compounds. | ||||||
Federal contracts 1
Agencies that awarded contracts to this company, from USAspending.gov. Dollars are obligated amounts as reported, not estimates; $1.5M in the latest fiscal year shown per agency.
| Agency | Obligated | Fiscal year | Awards | Trend | Largest award |
|---|---|---|---|---|---|
| Department of Health and Human Services
National Institutes of Health |
$1.5M | FY 2025 | 1 | $8.5M → $1.3M → $1.5M | 75N93023C00052 |
TO CONDUCT CLINICAL DEVELOPMENT OF A COMPOUND FOR THE TREATMENT OF COVID-19. | |||||
Alerts are coming
Get an email when ALGS's disclosed suppliers or customers change. Join the list and we'll tell you when alerts launch. One email, no spam.